These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
289 related articles for article (PubMed ID: 21658239)
1. GP88 (PC-Cell Derived Growth Factor, progranulin) stimulates proliferation and confers letrozole resistance to aromatase overexpressing breast cancer cells. Abrhale T; Brodie A; Sabnis G; Macedo L; Tian C; Yue B; Serrero G BMC Cancer; 2011 Jun; 11():231. PubMed ID: 21658239 [TBL] [Abstract][Full Text] [Related]
2. Targeting the receptor tyrosine kinase RET in combination with aromatase inhibitors in ER positive breast cancer xenografts. Andreucci E; Francica P; Fearns A; Martin LA; Chiarugi P; Isacke CM; Morandi A Oncotarget; 2016 Dec; 7(49):80543-80553. PubMed ID: 27602955 [TBL] [Abstract][Full Text] [Related]
3. New cell culture model for aromatase inhibitor-resistant breast cancer shows sensitivity to fulvestrant treatment and cross-resistance between letrozole and exemestane. Hole S; Pedersen AM; Hansen SK; Lundqvist J; Yde CW; Lykkesfeldt AE Int J Oncol; 2015 Apr; 46(4):1481-90. PubMed ID: 25625755 [TBL] [Abstract][Full Text] [Related]
4. AKT-aro and HER2-aro, models for de novo resistance to aromatase inhibitors; molecular characterization and inhibitor response studies. Wong C; Wang X; Smith D; Reddy K; Chen S Breast Cancer Res Treat; 2012 Jul; 134(2):671-81. PubMed ID: 22706627 [TBL] [Abstract][Full Text] [Related]
5. Efficacy and mechanism of action of Proellex, an antiprogestin in aromatase overexpressing and Letrozole resistant T47D breast cancer cells. Gupta A; Mehta R; Alimirah F; Peng X; Murillo G; Wiehle R; Mehta RG J Steroid Biochem Mol Biol; 2013 Jan; 133():30-42. PubMed ID: 22939887 [TBL] [Abstract][Full Text] [Related]
6. The role of microRNA-128a in regulating TGFbeta signaling in letrozole-resistant breast cancer cells. Masri S; Liu Z; Phung S; Wang E; Yuan YC; Chen S Breast Cancer Res Treat; 2010 Nov; 124(1):89-99. PubMed ID: 20054641 [TBL] [Abstract][Full Text] [Related]
7. GDNF-RET signaling in ER-positive breast cancers is a key determinant of response and resistance to aromatase inhibitors. Morandi A; Martin LA; Gao Q; Pancholi S; Mackay A; Robertson D; Zvelebil M; Dowsett M; Plaza-Menacho I; Isacke CM Cancer Res; 2013 Jun; 73(12):3783-95. PubMed ID: 23650283 [TBL] [Abstract][Full Text] [Related]
8. MicroRNA-125b upregulation confers aromatase inhibitor resistance and is a novel marker of poor prognosis in breast cancer. Vilquin P; Donini CF; Villedieu M; Grisard E; Corbo L; Bachelot T; Vendrell JA; Cohen PA Breast Cancer Res; 2015 Jan; 17(1):13. PubMed ID: 25633049 [TBL] [Abstract][Full Text] [Related]
9. Synergistic activity of letrozole and sorafenib on breast cancer cells. Bonelli MA; Fumarola C; Alfieri RR; La Monica S; Cavazzoni A; Galetti M; Gatti R; Belletti S; Harris AL; Fox SB; Evans DB; Dowsett M; Martin LA; Bottini A; Generali D; Petronini PG Breast Cancer Res Treat; 2010 Nov; 124(1):79-88. PubMed ID: 20054642 [TBL] [Abstract][Full Text] [Related]
10. The aromatase inhibitor letrozole and inhibitors of insulin-like growth factor I receptor synergistically induce apoptosis in in vitro models of estrogen-dependent breast cancer. Lisztwan J; Pornon A; Chen B; Chen S; Evans DB Breast Cancer Res; 2008; 10(4):R56. PubMed ID: 18611244 [TBL] [Abstract][Full Text] [Related]
11. Growth inhibition of estrogen receptor-positive and aromatase-positive human breast cancer cells in monolayer and spheroid cultures by letrozole, anastrozole, and tamoxifen. Kijima I; Itoh T; Chen S J Steroid Biochem Mol Biol; 2005 Dec; 97(4):360-8. PubMed ID: 16263272 [TBL] [Abstract][Full Text] [Related]
12. Nonhypoxic regulation and role of hypoxia-inducible factor 1 in aromatase inhibitor resistant breast cancer. Kazi AA; Gilani RA; Schech AJ; Chumsri S; Sabnis G; Shah P; Goloubeva O; Kronsberg S; Brodie AH Breast Cancer Res; 2014 Jan; 16(1):R15. PubMed ID: 24472707 [TBL] [Abstract][Full Text] [Related]
14. Dietary genistein negates the inhibitory effect of letrozole on the growth of aromatase-expressing estrogen-dependent human breast cancer cells (MCF-7Ca) in vivo. Ju YH; Doerge DR; Woodling KA; Hartman JA; Kwak J; Helferich WG Carcinogenesis; 2008 Nov; 29(11):2162-8. PubMed ID: 18632754 [TBL] [Abstract][Full Text] [Related]
15. HDAC inhibitor entinostat restores responsiveness of letrozole-resistant MCF-7Ca xenografts to aromatase inhibitors through modulation of Her-2. Sabnis GJ; Goloubeva OG; Kazi AA; Shah P; Brodie AH Mol Cancer Ther; 2013 Dec; 12(12):2804-16. PubMed ID: 24092810 [TBL] [Abstract][Full Text] [Related]
16. Effects of novel retinoic acid metabolism blocking agent (VN/14-1) on letrozole-insensitive breast cancer cells. Belosay A; Brodie AM; Njar VC Cancer Res; 2006 Dec; 66(23):11485-93. PubMed ID: 17145897 [TBL] [Abstract][Full Text] [Related]
17. [Establishment of an aromatase inhibitor letrozole-resistant breast cancer cell model]. Chen HY; Liu ZH Zhonghua Zhong Liu Za Zhi; 2013 Jun; 35(6):423-8. PubMed ID: 24119901 [TBL] [Abstract][Full Text] [Related]
18. Aromatase Inhibitor-Mediated Downregulation of INrf2 (Keap1) Leads to Increased Nrf2 and Resistance in Breast Cancer. Khatri R; Shah P; Guha R; Rassool FV; Tomkinson AE; Brodie A; Jaiswal AK Mol Cancer Ther; 2015 Jul; 14(7):1728-37. PubMed ID: 25976679 [TBL] [Abstract][Full Text] [Related]
19. AIB1:ERα transcriptional activity is selectively enhanced in aromatase inhibitor-resistant breast cancer cells. O'Hara J; Vareslija D; McBryan J; Bane F; Tibbitts P; Byrne C; Conroy RM; Hao Y; Gaora PÓ; Hill AD; McIlroy M; Young LS Clin Cancer Res; 2012 Jun; 18(12):3305-15. PubMed ID: 22550166 [TBL] [Abstract][Full Text] [Related]
20. PC cell-derived growth factor mediates tamoxifen resistance and promotes tumor growth of human breast cancer cells. Tangkeangsirisin W; Hayashi J; Serrero G Cancer Res; 2004 Mar; 64(5):1737-43. PubMed ID: 14996734 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]